

B¹ A preferred myeloid cell specific promoter is all or a functional portion of isolated or recombinant SEQ ID NO:1, such that the sequence is sufficient to direct myeloid cell specific expression of a gene. More preferably, the myeloid cell specific promoter of the present invention is the -946 to +74 region in FIG. 1 that is upstream (5') of the CD11d gene, as identified by positions 225 to 1244 of SEQ ID NO:1. In particular, the present invention relates to portions of this sequence that are sufficient to direct myeloid cell specific expression of a heterologous gene, and also includes modifications of this sequence that retain sufficient activity to direct myeloid cell specific expression of a heterologous gene. More preferably, the invention relates to the region from -173 to +74 that is upstream (5') of the CD11d gene in FIG. 1 (positions 998 to 1244 of SEQ ID NO:1). The invention further includes all or a functional portion of isolated or recombinant SEQ ID NO:1, wherein the sequence comprises one or more modifications, such that the modified sequence retains sufficient activity to direct myeloid cell specific expression of a gene.

Paragraph starting on page 3, line 10:

B² A preferred *cis*-acting element is the -173 to +74 region that is upstream (5') of the CD11d gene as shown in FIG. 1 (positions 998 to 1244 of SEQ ID NO:1). Also preferred is the -72 to -40 region (positions 1099 to 1131 of SEQ ID NO:1), more specifically, the -63 to -40 region (positions 1108 to 1131 of SEQ ID NO:1), that is upstream (5') of the CD11d gene as shown in FIG. 1. In particular, the invention is directed to *cis*-acting elements that positively influence the CD11d promoter, increasing the activity of the promoter.

Paragraph starting on page 3, line 15:

B3
Cis-acting elements that negatively influence the CD11d promoter are also incorporated as part of the present invention. Particularly, the present invention relates to the -591 to -378 region that is upstream (5') of the CD11d gene as shown in FIG. 1 (positions 580 to 793 of SEQ ID NO:1). This *cis*-acting element contains a cell-specific silencer element.

Paragraph starting on page 5, line 5:

B4
FIG. 1 shows the DNA sequence of the CD11d 5'flanking region and exons 1-7 and shows the sequence analysis data for the -946 to +74 CD11d promoter region (positions 225 to 1244 of SEQ ID No: 1). The complete sequence in lowercase for introns 1, 3 and 4, and the sequence at the intron-exon junctions for introns 2, 5, 6 and 7 and their sizes are shown. Consensus gt/ag splice junctions are underlined. Putative binding sites for transcription factors are underlined and indicated above the sequence. The transcriptional start site (+1), the ATG translational start site (boxed), and protein sequence (SEQ ID NO:2) are shown.

Paragraph starting on page 8, line 10:

B5
It has been surprisingly and unexpectedly discovered that the -946 to +74 region (positions 225 to 1244 of SEQ ID NO:1), as illustrated in FIG. 1., contains the promoter activity for the CD11d gene. More specifically, it has been surprisingly and unexpectedly discovered that the -173 to +74 region (positions 998 to 1244 of SEQ ID NO:1) is sufficient to confer leukocyte-specific expression of a gene in myeloid cells, when the gene is a heterologous gene, such as a luciferase reporter gene.

Paragraph starting on page 9, line 18:

6
A preferred *cis*-acting element is the -173 to +74 region that is upstream (5') of the CD11d gene as shown in FIG. 1 (positions 998 to 1244 of SEQ ID NO:1). This *cis*-acting element regulates cell-specific downregulation of CD11d by 4-phorbol-12-myristate 13-acetate (PMA). Also preferred is the -72 to -40 (positions 1099 to 1131 of SEQ ID NO:1), more specifically, the -63 to -40 (positions 1108 to 1131 of SEQ ID NO:1) that is upstream (5') of the CD11d gene. This *cis*-acting element binds the transcription factor Sp1. It has been found that purified Sp1 binds at the -63 to -40 (positions 1108 to 1131 of SEQ ID NO:1) region that is upstream (5') of the CD11d gene; whereas crude protein extract that contains Sp1 binds to a larger region, namely, the -72 to -40 (positions 1099 to 1131 of SEQ ID NO:1) region that is upstream (5') of the CD11d gene. It has been discovered that a functional Sp1 binding site is necessary for high levels of CD11d promoter activity. The presence of these *cis*-acting elements positively influence the CD11d promoter, increasing the activity of the promoter.

Paragraph starting on page 10, line 4:

37
Cis-acting elements that negatively influence the CD11d gene are also incorporated as part of the present invention. Most notably, it has been discovered that the -591 to -378 region shown in FIG. 1 (positions 580 to 793 of SEQ ID NO:1) contains a cell-specific silencer element. As described in the following Examples, evidence of a cell-specific silencer element within the -591 to -378 region (positions 580 to 793 of SEQ ID NO:1) that serves to downregulate CD11d expression in Jurkat and IM-9 cells was found.

Paragraph starting on page 14, line 28:

B² A series of 5'-unidirectional deletions of the -946 to +74 region (positions 225 to 1244 of SEQ ID No: 1) of the CD11d promoter were prepared by the polymerase chain reaction (PCR) with oligonucleotide primers specific to this region and fused to the firefly luciferase gene (*luc*) in plasmid pGL3-Basic (Promega Corp., Madison, WI). The forward and reverse primers used in the PCR contained XhoI and HindIII restriction sites, respectively, for cloning of the final PCR product into pGL3-Basic. The -500 to +93 region of the CD11a promoter (positions 671 to 1263 of SEQ ID NO:1), the -500 to +50 region of the CD11b promoter (positions 671 to 1220 of SEQ ID NO:1), and the -196 to +30 region of the CD11c promoter (positions 975 to 1200 of SEQ ID NO:1) were prepared in a similar manner and ligated into pGL3-Basic by the methods of Noti *et al.* and Noti. Noti, J. D., *et al.*, Mol. Cell. Biol. 16:2940-2950 (1996); Noti, J. D., J. Biol. Chem. 272:24038-24045 (1997).

Paragraph starting on page 15, line 9:

B⁹ A primer containing a deletion of the Sp1-binding site (-63 to -40, positions 1108 to 1131 of SEQ ID NO:1) was used in the PCR to construct reporter plasmid CD11d(-173/+74)(-63/-40)-*luc*. The plasmid pPacSp1, which expresses Sp1 from the *Drosophila* actin promoter, and the control plasmid pPacO, containing only the *Drosophila* actin promoter, were additionally utilized. The construction of plasmids that express Sp2 and Sp3 from the actin promoter (plasmids pPacSp2 and pPacSp3, respectively) were prepared as described by Noti, J. D., J. Biol. Chem. 272:24038-24045 (1997). The integrity of all constructs was verified by DNA sequence analysis.

Paragraph starting on page 16, line 17:

B10 The PCR was performed to prepare a double-stranded probe to the -173 to +74 region (positions 998 to 1244 of SEQ ID NO:1) and one primer was labeled with [$\gamma^{32}\text{P}$]ATP. The probe was purified by electrophoresis through a 2% agarose gel on to NA45-DEAE paper according to the manufacturer's instructions (Schleicher and Schuell, Keene, NH). Approximately $1-2 \times 10^5$ cpm of probe (1-2 ng), and either 50 μg crude nuclear extract protein (prepared according to Noti *et al.*, DNA and Cell Biol. 11:123-138 (1992)) or 1 to 4 footprinting unit (fpu, concentration determined by the manufacturer) (Promega Corp., Madison, WI) of purified Sp1 protein, were incubated in a total volume of 50 μl binding buffer containing 0 or 5 μg poly d(I-C), 6.25 mM MgCl_2 , 50 mM KCl, 0.5 mM EDTA, 10% glycerol, 0.5 mM DTT, and 25 mM Tris-HCl, pH 8.0, for 15 min. at room temperature. Then 50 μl of 5 mM CaCl_2 10 mM MgCl_2 , and 0.2-2 units of DNase I were added. After 1 min. at room temperature the reaction was stopped with 90 μl of 0.2 M NaCl, 0.03 M EDTA, 1% SDS, 10 μg *Escherichia coli* tRNA, phenol\chloroform extracted, ethanol precipitated, and analyzed on a sequencing gel.

Paragraph starting on page 17, line 20:

B11 5' CTGGGAGAAGGAAGCCAGGTC 3' (SEQ ID NO:9) (for first strand synthesis from the denatured DNAs), which spanned the region -171 to -151 (positions 1000 to 1020 of SEQ ID NO:1); primer #2,

Paragraph starting on page 17, line 23:

B12 5' CAGGTTGTGGAGGGGGACAGAATGAGG 3' (SEQ ID NO:10) (amplification primer), which spanned the region -146 to -120 (positions 1025 to 1051 of SEQ ID NO:1); and primer #3,

Paragraph starting on page 17, line 25:

5' GGTTGTGGAGGGGGACAGAATGAGGGTTTTTCC 3' (SEQ ID NO:11)

B13 (labeling primer), which spanned the region -144 to -112 (positions 1027 to 1059 of SEQ ID NO:1). First strand synthesis was done for 30 min. at 60°C. The DNAs were denatured for 4 min. at 95°C and amplified by the PCR (18 cycles) as follows: 1 min. at 95°C, 2 min. at 68°C, and 3 min. at 76°C. An extra 5 seconds was added to each extension step and the final extension proceeded for 10 min. Two additional cycles of the PCR were carried out to label the PCR products as follows: 1 min. at 95°C, 2 min. at 69°C, and 10 min. at 76°C. An approximately equal amount of each sample was loaded on a sequencing gel. The band intensities were analyzed on a Storm Phosphoimager.

Paragraph starting on page 18, line 7:

B14 The -381 to +74 region of CD11d (positions 790 to 1096 of SEQ ID NO:1) was amplified by the PCR and cloned into the XhoI and HindIII sites of pGEM-7Zf(-) (Promega Corp., Madison, WI). This clone was linearized with XhoI, and used as template in an in vitro transcription system to prepare a 562 bp RNA probe (Riboprobe, Promega Corp., Madison, WI) that spanned this region according to the manufacturer's instructions. The RNA probe was labeled with [α -32P]UTP to a specific activity of 7×10^7 cpm/ μ g, loaded on to a 5% polyacrylamide/8 M urea gel, and subsequently eluted into buffer containing 0.5 M ammonium acetate/1 mM EDTA/0.2% SDS. Approximately $1-2 \times 10^5$ cpm of probe was annealed to either 20 μ g total RNA from HL60 or yeast cells and hybridized in 20 μ l of 80% deionized formamide/100 mM sodium citrate pH 6.4/300 mM sodium acetate pH 6.4/1mM EDTA for 16-18 hr. at 44°C. Following hybridization, the

B14
annealed probe/RNA complexes were treated with various concentrations of RNase A/T1 (Ambion, Inc., Austin, TX), extracted with proteinase K and phenol/chloroform, and analyzed on a 5% polyacrylamide/8 M urea gel.

Paragraph starting on page 18, line 22:

B15
For S1 nuclease analysis, a 247 nucleotide single-stranded DNA probe corresponding to the -173 to +74 region of CD11d (positions 998 to 1244 of SEQ ID NO:1) was prepared by extension of a 22 nucleotide long primer on the luciferase reporter plasmid containing this region. The probe was end-labeled with [α -³²P]ATP (probe specific activity of 5.3×10^7 cpm/ μ g). Hybridization of the DNA probe, prepared with the Prime-A-Probe Kit (Ambion, Inc., Austin, TX), to either 500 ng THP1 poly (A+) RNA or 20 μ g yeast total RNA and subsequent digestion with S1 nuclease was performed according to the instructions in the S1-Assay Kit provided by the manufacturer (Ambion Inc, Austin, TX). A second antisense DNA probe, 99 nucleotides long with the 5'-end positioned 19 bp upstream of the ATG codon, was chemically synthesized, end-labeled with [α -³²P]ATP (probe specific activity of 2.88×10^8 cpm/ μ g) and hybridized with HL60 poly (A+) RNA or yeast total RNA.

Paragraph starting on page 20, line 3:

B16
As illustrated in FIG. 1, the CD11d genomic clone was found to contain exons 1-7 not previously known in the art, which correspond to nucleotides 1-704 of the CD11d coding sequence (positions 1171-1874 of SEQ ID NO:1). Exon 8 and possibly another exon is predicted to lie between nucleotides 704-982 of CD11d (positions 1874-

B16
2152 of SEQ ID NO:1), which would be consistent with an average exon size of 100-150 nucleotides.

Paragraph starting on page 21, line 29:

B17
CD11d is expressed predominately on myeloid cells and exposure to phorbol ester led to its downregulation from the cell surface. THP1 cells were transfected with construct CD11d(-946/+74)-*luc*, which contains the -946 to +74 region of CD11d (positions 225 to 1244 of SEQ ID NO:1) fused to the luciferase gene, and 24 hr. post-transfection were exposed to PMA for varying times, as shown in FIG. 4. Transfected THP1 cells exposed to PMA for up to 10 hr. showed no decrease in luciferase expression, however, after 24 hr., luciferase activity decreased 55%, as shown in FIG. 4. For comparison, expression of CD11a, which is detected in all leukocytes, and CD11c, which is predominately detected in myeloid cells, were monitored following transfection of the CD11a-*luc* and CD11c-*luc* constructs, respectively. Luciferase activity from CD11a-*luc* in THP1 cells was increased 4.5-fold, and luciferase activity from CD11c-*luc* was increased 8.3-fold in the presence of PMA, as illustrated in FIG. 4. These results show that chronic, rather than acute, exposure to PMA leads to downregulation of CD11d expression (and upregulation of CD11a and CD11c expression as expected), and that one or more *cis*-acting elements within the -946 to +74 region (positions 225 to 1244 of SEQ ID NO:1) mediates this effect.

Paragraph starting on page 22, line 15:

B18
The -946 to +74 region (positions 225 to 1244 of SEQ ID NO:1) was further examined to localize the *cis*-acting element(s) responsible for PMA-induced downregulation of CD11d and/or other elements that influence either basal or cell-specific

B7B
www
expression. A series of CD11d reporter constructs containing progressively larger 5'-deletions was prepared and transfected into various cell lines. Luciferase expression from the constructs transfected into THP1 cells varied, but not significantly.

Paragraph starting on page 22, line 21:

B19
CD11d(-173/+74)-*luc*, which contains only the -173 to +74 region (positions 998 to 1244 of SEQ ID NO:1) of CD11d, retained all of the activity obtained with CD11d(-946/+74)-*luc* and was 43-fold higher than that obtained with the promoterless pGL-3 Basic plasmid, as shown in FIG. 5A. In contrast, luciferase expression in MCF-7 breast cancer cells transfected with these constructs was increased only 2.5 to 6.4-fold over that obtained with pGL-3 Basic as shown in FIG. 5B. Expression from CD11d(-946/+74)-*luc* transfected into the B-cell line IM-9 was also reduced, as luciferase activity was only 8.1-fold over that obtained from pGL3-Basic, as illustrated in FIG. 5C. CD11d(-946/+74)-*luc* expression in the T-cell line Jurkat, was also reduced, although expression was higher than anticipated as it was 18-fold greater than that obtained from pGL3-Basic, as shown in FIG. 5D. Deletion of the -591 to -378 region (positions 580 to 793 of SEQ ID NO:1) resulted in significant increases in luciferase expression in both IM-9 and Jurkat cells to approximately the level of expression of CD11d(-173/+74)-*luc* in THP1 cells. See FIGS 5C and 5D, compare CD11d(-591/+74)-*luc* with CD11d(-378/+74)-*luc*. This result indicates the presence of a cell-specific silencer. Luciferase expression from each of the CD11d-*luc* 5'-deletion constructs transfected into THP1 cells was reduced to approximately the same extent after exposure to PMA, as shown in FIG. 5A. A similar response to PMA was confirmed in another myeloid cell line, HL60, wherein it was discovered that PMA reduces expression in HL60 by 77%. This shows that a PMA-

B19
cor

responsive *cis*-acting element(s) lies within the -173 to +74 region (positions 998 to 1244 of SEQ ID NO:1), since CD11d(-173/+74)-*luc*, which contains only this region, responds to PMA. In contrast, luciferase expression in IM-9 and Jurkat cells transfected with the CD11d-*luc* 5'-deletion constructs was not reduced by PMA, but instead, was increased 1.5 to 2.5-fold, see FIGS. 5C and 5D. Together, these results show two regions of CD11d that regulate its expression. The -591 to -378 (positions 580 to 793 of SEQ ID NO:1) region may contain a cell-specific silencer element, and the -173 to +74 region (positions 998 to 1244 of SEQ ID NO:1) regulates cell-specific downregulation of CD11d by PMA.

Paragraph starting on page 23, line 21:

B20

DNase I footprint analysis was performed to determine whether DNA binding proteins interact with the -173 to +74 region (positions 998 to 1244 of SEQ ID NO:1). When nuclear extracts prepared from unstimulated and PMA-stimulated THP1 cells were added to a probe labeled on the coding strand, strong protection of the -63 to -40 region (positions 1108 to 1131 of SEQ ID NO:1) was revealed. This same region was also protected by nuclear extracts prepared from unstimulated and PMA-stimulated Jurkat and IM-9 cells. When a probe labeled on the non-coding strand was used, strong protection of an overlapping region, -72 to -45 (positions 1099 to 1126 of SEQ ID NO:1), was detected with unstimulated and PMA-stimulated nuclear extracts from all three cell lines. DNA sequence analysis of the overlapping region revealed the presence of an Sp1 binding site.

Paragraph starting on page 24, line 1:

B21

In vitro DNase I footprint analysis showed that purified Sp1 protein could also protect the -63 to -40 region positions 1108 to 1131 of SEQ ID NO:1.

B21
cont

Electrophoretic mobility shift analysis (EMSA) with THP1 nuclear extract protein and a probe to the -63 to -40 region positions 1108 to 1131 of SEQ ID NO:1 revealed a protein/DNA complex that could be supershifted with anti-Sp1 antibody.

Paragraph starting on page 24, line 7:

B22

To determine whether the Sp1-binding site is important for CD11d expression, this site was deleted from CD11d(-173/+74)-*luc* and its effect on expression was monitored in transfected cells. Deletion of the -63 to -40 region (positions 1108 to 1131 of SEQ ID NO:1) resulted in reduction of luciferase expression from CD11d(-173/+74)(-63/-40)-*luc* to 24% in transfected THP1 cells, as shown in FIG. 6A. When transfected THP1 cells were exposed to PMA, expression from CD11d(-173/+74)-*luc* was reduced to 30%. Deletion of the -63 to -40 region (positions 1108 to 1131 of SEQ ID NO:1) further reduced luciferase expression from CD11d(-173/+74)(-63/-40)-*luc* in PMA-stimulated THP1 cells only an additional 7%, as shown in FIG. 6A. Luciferase expression from CD11d(-173/+74)(-63/-40)-*luc* in transfected IM-9 and Jurkat cells was similarly reduced to 20% and 24%, respectively, as illustrated by FIGS 6B and 6C. Although PMA did not reduce the expression of luciferase from CD11d(-173/+74)-*luc* transfected into IM-9 and Jurkat cells, expression from CD11d(-173/+74)(-63/-40)-*luc* was reduced to 18% and 20%, respectively, as shown in FIGS. 6B and 6C. These results show that the -63 to -40 region (positions 1108 to 1131 of SEQ ID NO:1) is essential for CD11d promoter activity in both myeloid and non-myeloid cells. Further, the inability of PMA to reduce luciferase expression from CD11d(-173/+74)-*luc* in non-myeloid cells is dependent on the integrity of this region.

Paragraph starting on page 24, line 27:

B23 To show that CD11d promoter activity is mediated through an interaction of Sp1 with the -63 to -40 region (positions 1108 to 1131 of SEQ ID NO:1), *Drosophila* cells, which are deficient in Sp-related proteins, were cotransfected with pPacSp1 along with CD11d(-173/+74)-*luc*, as shown in FIG. 7.

Paragraph starting on page 25, line 22:

B24 The above results show that cell-specific downregulation of CD11d promoter activity is mediated through one or more *cis* elements within the -173 to +74 region (positions 998 to 1244 of SEQ ID NO:1). The inability of IM-9 and Jurkat cells to maintain CD11d expression in the presence of PMA when the Sp1-binding site was deleted indicated that Sp1 was a necessary factor involved in this response. Further, the possibility that loss of Sp1-binding was linked to downregulation of CD11d promoter activity in THP1 cells exposed to PMA was suggested when the reduction in luciferase activity from CD11d(-173/+74)-*luc* in transfected THP1 cells exposed to PMA was found to be about the same as that obtained in unstimulated THP1 cells transfected with the Sp1-deleted construct CD11d(-173/+74)(-63/-40)-*luc* (70% vs. 76% reduction, respectively, as shown in FIG. 6).

Paragraph starting on page 26, line 3:

B25 In vivo genomic footprinting was performed to determine if selective Sp1-binding occurs on the CD11d promoter. Genomic DNA, methylated in vivo with dimethyl sulfate, was isolated from HL60, IM-9, and Jurkat cells that were either unstimulated or PMA-stimulated. DNA was also isolated from HL60 and Jurkat cells, stripped of bound protein, and methylated in vitro as controls. Analysis of the CD11d non-coding strand, as shown in FIG. 8, revealed hyposensitive sites in unstimulated HL60 DNA at positions -38,